The DOI matches its Crossref record.
Interleukin-6 Family of Cytokines Mediate Angiotensin II-induced Cardiac Hypertrophy in Rodent Cardiomyocytes
Open accessAbstract
This study was designed to investigate whether angiotensin II induces the interleukin (IL)-6 family of cytokines in cardiac fibroblasts and, if so, whether these cytokines can augment cardiac hypertrophy. Angiotensin II increased IL-6, leukemia inhibitory factor (LIF) and cardiotrophin-1 mRNA by 6.5-, 10.2-, and 2.0-fold, respectively, but did not affect IL-11, ciliary neurotrophic factor, or oncostatin M in cardiac fibroblasts. Enzyme-linked immunosorbent assay revealed that angiotensin II-stimulated conditioned medium from cardiac fibroblasts contained 9.3 ng/ml IL-6 at 24 h, which was 24-fold higher than the control. It phosphorylated gp130 and STAT3 in cardiomyocytes, which was reduced with RX435 (anti-gp130 blocking antibody). It increased [(3)H]phenylalanine uptake and cell area by 44% and 86% in cardiomyocytes compared with mock medium. RX435 suppressed these increases by 26% and 38%, while TAK044 (endothelin-A/B-R blocker) suppressed them by 52% and 52%, respectively. Antisense oligonucleotides against LIF and cardiotrophin-1 blocked their up-regulation, and attenuated the conditioned medium-induced increase in [(3)H]phenylalanine uptake by 21% and 13%, respectively. The combination of antisense oligonucleotides to LIF and cardiotrophin-1 decreased their uptake by 33%. These results indicated that angiotensin II induced IL-6, LIF, and cardiotrophin-1 in cardiac fibroblasts, and that these cytokines, particularly LIF and cardiotrophin-1, activated gp130-linked signaling and contributed to angiotensin II-induced cardiomyocyte hypertrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Cardiac Fibroblasts Regulate Myocardial Proliferation through β1 Integrin Signaling
Ieda, M., Tsuchihashi, T., Ivey, K. N., Ross, R. S., Hong, T.-T., Shaw, R. M., & Srivastava, D. (2009) · Developmental Cell · doi:10.1016/j.devcel.2008.12.007 · Cited by 580
Gene Expression in Fibroblasts and Fibrosis: Involvement in Cardiac Hypertrophy
Manabe, I., Shindo, T., & Nagai, R. (2002) · Circulation Research · doi:10.1161/01.res.0000046452.67724.b8 · Cited by 512
COVID-19 cytokine storm: the anger of inflammation
Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155151 · Cited by 461
“In a recent study, the first clinical evidence has shown that ACE inhibitors or ARB therapy in COVID-19 patients with hypertension were associated with a lower rate of disease severity, a trend toward lower IL-6 levels, and higher circulatory CD3+ and CD4+ T cells counts [39].”
InfluentialMeléndez, G. C., McLarty, J. L., Levick, S. P., Du, Y., Janicki, J. S., & Brower, G. L. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.148635 · Cited by 442
Cardiac fibroblasts: friend or foe?
Baudino, T. A., Carver, W., Giles, W., & Borg, T. K. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00023.2006 · Cited by 427
Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure
Hanna, A., & Frangogiannis, N. G. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07071-0 · Cited by 418
Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload
Takeda, N., Manabe, I., Uchino, Y., Eguchi, K., Matsumoto, S., Nishimura, S., Shindo, T., Sano, M., Otsu, K., Snider, P., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40295 · Cited by 389
Self-citationIntramyocardial Fibroblast Myocyte Communication
Kakkar, R., & Lee, R. T. (2010) · Circulation Research · doi:10.1161/circresaha.109.207456 · Cited by 333
Cardiac neural crest cells contribute to the dormant multipotent stem cell in the mammalian heart
Tomita, Y., Matsumura, K., Wakamatsu, Y., Matsuzaki, Y., Shibuya, I., Kawaguchi, H., Ieda, M., Kanakubo, S., Shimazaki, T., Ogawa, S., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504061 · Cited by 318
Self-citationMolecular regulation of cardiac hypertrophy
Barry, S. P., Davidson, S. M., & Townsend, P. A. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.02.020 · Cited by 306
Sano, M., Fukuda, K., Sato, T., Kawaguchi, H., Suematsu, M., Matsuda, S., Koyasu, S., Matsui, H., Yamauchi-Takihara, K., Harada, M., et al. (2001) · Circulation Research · doi:10.1161/hh2001.098873 · Cited by 298
Self-citationMolecular targets and regulators of cardiac hypertrophy
Rohini, A., Agrawal, N., Koyani, C. N., & Singh, R. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2009.11.012 · Cited by 295
Systemic inflammation in heart failure – The whys and wherefores
Yndestad, A., Kristian Damås, J., Øie, E., Ueland, T., Gullestad, L., & Aukrust, P. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9196-2 · Cited by 294
Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis
Fischer, P., & Hilfiker-Kleiner, D. (2007) · Basic Research in Cardiology · doi:10.1007/s00395-007-0674-z · Cited by 272
Fairweather, D., Frisancho-Kiss, S., Yusung, S. A., Barrett, M. A., Davis, S. E., Gatewood, S. J. L., Njoku, D. B., & Rose, N. R. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63241-5 · Cited by 198
Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats
Fredersdorf, S., Thumann, C., Ulucan, C., Griese, D. P., Luchner, A., Riegger, G. A. J., Kromer, E. P., & Weil, J. (2004) · Cardiovascular Pathology · doi:10.1016/s1054-8807(03)00109-1 · Cited by 115
Zouein, F. A., Altara, R., Chen, Q., Lesnefsky, E. J., Kurdi, M., & Booz, G. W. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00036 · Cited by 82
Acute myotube protein synthesis regulation by IL-6-related cytokines
Gao, S., Durstine, J. L., Koh, H.-J., Carver, W. E., Frizzell, N., & Carson, J. A. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00112.2017 · Cited by 69
Metadata
- Authors
- Sano, M., Fukuda, K., Kodama, H., Pan, J., Saito, M., Matsuzaki, J., Takahashi, T., Makino, S., Kato, T., & Ogawa, S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-09
- Volume
- 275
- Issue
- 38
- Pages
- 29717-29723
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1968202984
- Cited by
- 233
- References
- 0
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.